Neoadjuvant transarterial infusion chemotherapy with FOLFOX could improve outcomes of resectable BCLC stage A/B hepatocellular carcinoma patients beyond Milan criteria: An interim analysis of a multi-center, phase 3, randomized, controlled clinical trial.Shaohua Li, Rong Guo, Jingwen Zou et al.|Journal of Clinical Oncology|2021Cited by 30
Transarterial infusion chemotherapy with FOLFOX for advanced hepatocellular carcinoma: a multi-center propensity score matched analysis of real-world practiceShaohua Li, Rong Guo, Jie Mei et al.|HepatoBiliary Surgery and Nutrition|2021Cited by 26
Postoperative adjuvant transarterial infusion chemotherapy with FOLFOX could improve outcomes of hepatocellular carcinoma patients with microvascular invasion: A preliminary report of a phase III, randomized, controlled clinical trial.Shaohua Li, Rong Guo, Wei Wei et al.|Journal of Clinical Oncology|2020Cited by 11
Risk factors of extra-hepatic progression after transarterial chemoembolization for hepatocellular carcinoma patients: a retrospective study in 654 casesShaohua Li, Rong Guo, Qiaoxuan Wang et al.|Journal of Cancer|2019Cited by 5
Abstract 1622: Dovitinib preferentially targets endothelial cells rather than cancer cells for the inhibition of hepatocellular carcinoma growth and metastasis.Zhiyuan Chen, Rong Guo, Ming Shi et al.|Cancer Research|2013Cited by 0